ライフサイエンスコーパス: cell-based therapy

1 cells (MSCs) are a promising candidate for a cell-based therapy.

2 cells for disease modeling and, ultimately, cell-based therapy.

3 d have broad applicability for hematopoietic cell-based therapy.

4 ation, and their suitability for programs of cell-based therapy.

5 restoration in partial LSCD is possible with cell-based therapy.

6 ides a strategy to sensitize RMS cells for T-cell-based therapy.

7 disorders may now be compelling targets for cell-based therapy.

8 from IRI and suggests their potential use in cell-based therapy.

9 potentially provide an autologous source for cell-based therapy.

10 ngraftment, which is a limiting step of stem cell-based therapy.

11 ease and the implications for trials of Treg cell-based therapy.

12 tforms for disease study, drug screening and cell-based therapy.

13 the use of hiPSC-CM for disease modeling and cell-based therapy.

14 as prognostic markers and also as exogenous cell-based therapy.

15 e attractive targets for stem and progenitor cell-based therapy.

16 oth mechanistic studies and screening of new cell based therapies.

17 edical research models and for gene and stem cell based therapies.

18 high-quality cells remains an impediment to cell-based therapies.

19 ing, risk prediction, and cell selection for cell-based therapies.

20 ate and function, and for the development of cell-based therapies.

21 may impact future design of autologous stem cell-based therapies.

22 H) 1 and IDH2, antibody-based therapies, and cell-based therapies.

23 ll-based monitoring of cancer cells and stem cell-based therapies.

24 sed in DM, potentially exacerbating impaired cell-based therapies.

25 ally improve efficacy of stem and progenitor cell-based therapies.

26 industry is critical for generating new stem cell-based therapies.

27 h as drug screening and potentially also for cell-based therapies.

28 tion would greatly facilitate development of cell-based therapies.

29 ro culture is a common prerequisite for stem cell-based therapies.

30 d could instruct improved protocols for stem cell-based therapies.

31 t importance for application to regenerative cell-based therapies.

32 Cs is particularly attractive for allogeneic cell-based therapies.

33 edge gaps and safety concerns regarding stem cell-based therapies.

34 n essential prerequisite for developing stem cell-based therapies.

35 ation--offer renewed hope for development of cell-based therapies.

36 cines and for the development of effective T cell-based therapies.

37 el treatment strategies for future gene- and cell-based therapies.

38 y allow for future widespread application of cell-based therapies.

39 eful preclinical model for testing gene- and cell-based therapies.

40 omplex will allow better design of gene- and cell-based therapies.

41 diverse lineages for future patient-specific cell-based therapies.

42 in preclinical and clinical applications of cell-based therapies.

43 ic diseases makes them attractive for use in cell-based therapies.

44 maging can be used to non-invasively monitor cell-based therapies.

45 udies of skeletal biology and development of cell-based therapies.

46 is tumor is a candidate for virus-specific T cell-based therapies.

47 improving our ability to achieve successful cell-based therapies.

48 ate clinically relevant cells for autologous cell-based therapies.

49 n vitro disease modeling and potentially for cell-based therapies.

50 provides a critical opportunity for refining cell-based therapies.

51 used as scaffolds in tissue engineering and cell-based therapies.

52 e, ITNKs may represent a new cell source for cell-based therapies.

53 argeting cellular pathways to gene-based and cell-based therapies.

54 tcomes in the treatment of lung disease with cell-based therapies.

55 e potential role of cortical interneurons in cell-based therapies.

56 disease modeling, regenerative medicine and cell-based therapies.

57 ts a promising approach to improve safety of cell-based therapies.

58 he forefront of the development of gene- and cell-based therapies.

59 intact cell sheets has shown promise in many cell-based therapies.

60 aluable tool for researchers developing stem cell-based therapies.

61 etabolic disorders foster advanced gene- and cell-based therapies.

62 icines, attention is increasingly turning to cell-based therapies.

63 cumvent the hurdles of traditional gene- and cell-based therapies.

64 of iPS-H, and may be applicable to many stem cell-based therapies.

65 lication in a host of tissue engineering and cell-based therapies.

66 valuable tool with which to evaluate various cell-based therapies.

67 Cs following TBI might offer new avenues for cell-based therapy, additional intervention is required

68 Clinical trials of bone marrow cell-based therapies after acute myocardial infarction (

69 ecule antagonism of GSK3beta, which enhanced cell-based therapy after vascular injury.

70 implications for improving the efficacy of T cell-based therapies against chronic infectious diseases

71 therapy may thus be needed with emerging NK cell-based therapies against hematopoietic malignancies.

72 Cell-based therapies against HIV/AIDS have been gaining

73 ogramming, have shown enormous potential for cell-based therapies against intractable diseases such a

74 ty of adult spinal cord and the potential of cell-based therapies against neuropathic pain.

75 These data suggest that stem cell-based therapies aimed to engineer tissue in vivo ma

76 ate the outcome of stem cell- and progenitor cell-based therapies aimed to restore defunct muscle.

77 associated with retinal diseases makes stem-cell-based therapies an attractive strategy for personal

78 for genetic engineering, development of stem cell-based therapies and basic research on pluripotency

79 ential to enable a new wave of sophisticated cell-based therapies and diagnostics.

80 d cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infe

81 observations have direct implications for NK cell-based therapies and highlight the requirement to co

82 ENS; information required for development of cell-based therapies and models of enteric neuropathies.

83 eating cutaneous wounds, with an emphasis on cell-based therapies and skin transplantation.

84 n is essential for the improvement of immune cell-based therapies and the development of rational com

85 ure are unknown and hamper their use both in cell-based therapy and basic research.

86 a potentially unlimited supply of cells for cell-based therapy and diagnostics.

87 ted by progress in the understanding of stem cell-based therapy and growth factor enhancement of the

88 no effective pharmacologic therapy, although cell-based therapy and other therapies currently being t

89 ith autologous tumor lysate-pulsed dendritic cell-based therapy and simultaneously reducing the tumor

90 ponent of genome-editing approaches, ex vivo cell-based therapies, and a diversity of fundamental res

91 ating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compou

92 e for advancements in developmental biology, cell-based therapy, and modeling of human disease.

93 apacities to replace the damaged skeleton in cell-based therapy, and permit further elucidation of th

94 topes make it a viable target for pursuing T cell-based therapy approaches.

95 Cell based therapies are required now to meet the critic

96 Cell-based therapies are a promising intervention for th

97 Cell-based therapies are a promising option in patients

98 RATIONALE: Cell-based therapies are a promising option in patients

99 Regenerative cell-based therapies are associated with limited myocard

100 KEY POINTS: While autologous stem cell-based therapies are currently being tested on elder

101 Cell-based therapies are emerging as a promising approac

102 Cell-based therapies are gaining increasing importance a

103 The present meta-analysis indicates that cell-based therapies are not only safe but also lead to

104 Although gene- and cell-based therapies are on the horizon for RP and Usher

105 Cell-based therapies are promising alternative therapeut

106 Gene- and cell-based therapies are promising strategies for the tr

107 NK cell-based therapies are promising treatments for blood

108 Several cell-based therapies are under pre-clinical and clinical

109 implications of our results for muscle stem cell-based therapy are discussed.

110 rative medicine (TE/RM) therapeutics include cell based therapies as well as engineered tissues and n

111 acilitate the purification of Tregs for both cell-based therapies as well as detailed studies of huma

112 ad applications for enhancing engraftment in cell-based therapies as well as restoring age- and stres

113 tem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlim

114 igen (HLA) molecules have been targeted by T cell-based therapies, but there has been little progress

115 tent stem cells (PSCs) hold great promise in cell-based therapy, but the genomic instability seen in

116 able approach to enhance the effects of stem cell-based therapies by improving cell retention and eng

117 have become an important tool for improving cell-based therapies by promoting cell survival and prot

118 g has the potential to enable more-effective cell-based therapies by using readily available cell sou

119 In particular, it helps T-cell-based therapy by enhancing the adaptive immune resp

120 Recent studies have shown that stem cell-based therapies can improve liver function in a mou

121 Stem-cell-based therapies can potentially reverse organ dysfu

122 seek to test the efficacy of a novel, safer cell-based therapy (CBT) employing ex vivo primed bone m

123 n MSCs may improve the efficiency of cardiac cell-based therapy (CBT).

124 Cell-based therapies (CBTs) are considered the effective

125 Vasculogenic cell-based therapy combined with tissue engineering is a

126 The pursuit of gene and cell-based therapy continues, and device use to help acu

127 ing on the stage of melanoma progression, NK cell-based therapies could be combined with pharmacologi

128 eprogramming ECs, are an ideal cell type for cell-based therapy designed to stimulate coronary collat

129 chwann cells promise to be a useful tool for cell-based therapies, disease modelling and drug discove

130 tremendous promise in tissue engineering and cell-based therapies due to their unique combination of

131 ration make these cells ideal candidates for cell-based therapies, especially for diseases associated

132 hotopheresis (ECP) is a widely used clinical cell-based therapy exhibiting efficacy in heterogenous i

133 Cell-based therapy exploits modified human cells to trea

134 plant is being applied to the development of cell-based therapies for a variety of CNS disorders.

135 commitment suggests their potential in stem cell-based therapies for acute and chronic lung diseases

136 red to exploit the full potential of myeloid cell-based therapies for AD.

137 Several cell-based therapies for adjunctive treatment of acute m

138 plications for the design of vaccine, Ab and cell-based therapies for autoimmunity, infectious diseas

139 l genome engineering holds great promise for cell-based therapies for cancer, HIV, primary immune def

140 atform for accelerated development of future cell-based therapies for cancer.

141 vital for guiding the future development of cell-based therapies for cardiac regeneration.

142 Successful implementation of gene- and cell-based therapies for CF airway disease requires know

143 w harvest, and discussing risks vs benefits, cell-based therapies for chronic stroke, and consent for

144 iPS) cells are an intriguing source for stem cell-based therapies for congenital and acquired heart d

145 iation will be a successful approach for new cell-based therapies for diabetes, such as those derived

146 dels and forms the basis for developing stem cell-based therapies for different cancers.

147 inforcing their potential for development of cell-based therapies for diseased endoderm-derived tissu

148 een primarily studied for the development of cell-based therapies for Duchenne muscular dystrophy, li

149 or the development of protein replacement or cell-based therapies for dystrophic epidermolysis bullos

150 ing and may stimulate the development of new cell-based therapies for excitable tissue repair.

151 lls (CSCs) is a critical step for developing cell-based therapies for heart failure patients.

152 Continued advances toward cell-based therapies for human disease generate a growin

153 tion potential and may be a useful model for cell-based therapies for infectious and non-infectious l

154 A major obstacle to using bone marrow cell-based therapies for ischemic cardiovascular disease

155 armaceutical applications and development of cell-based therapies for liver diseases.

156 on and limits the effectiveness of gene- and cell-based therapies for muscle disorders.

157 scle stem cells is possible, enabling future cell-based therapies for muscle-wasting diseases.

158 Cell-based therapies for myelin disorders, such as multi

159 uron development and to the establishment of cell-based therapies for neurological disease.

160 technology have engendered keen interest in cell-based therapies for neurological disorders.

161 ES cell-based therapies for neurological repair in TLE requ

162 t work that addresses key challenges of stem cell-based therapies for osteoarthritis and provide exam

163 Stem cell-based therapies for Parkinson's disease are moving

164 on of stem cells and the development of stem cell-based therapies for Parkinson's disease.

165 l in 1997 by Asahara and Isner, the field of cell-based therapies for peripheral arterial disease has

166 modelling inner ear disorders or developing cell-based therapies for profound hearing loss and balan

167 microenvironment may impact the potential of cell-based therapies for recovery and repair following C

168 be one of the most promising candidates for cell-based therapies for SCI.

169 ew, we describe recent approaches to develop cell-based therapies for the treatment of AMD.

170 A major obstacle in the application of cell-based therapies for the treatment of neuromuscular

171 ion of cell behavior and offering customized cell-based therapies for tissue engineering.

172 he challenges involved in the application of cell-based therapies for treatment of diabetic vascular

173 ide insights into the design of effective NK cell-based therapies for viral infections.

174 al stromal cells are being investigated as a cell-based therapy for a number of disease processes, wi

175 Our design of T-cell-based therapy for cancer has reflected efforts to i

176 e infarcted myocardium remain problematic in cell-based therapy for cardiovascular disease.

177 velopmental pathway and open a potential for cell-based therapy for corneal blindness.

178 e further research into the development of a cell-based therapy for deafness.

179 esent a potential for development of a novel cell-based therapy for glaucoma.

180 a potential for development of a novel stem cell-based therapy for glaucoma.

181 lay crucial roles in phenotypic responses to cell-based therapy for heart failure.

182 ed derivatives can potentially be applied to cell-based therapy for human diseases.

183 bitory controls has potential as a powerful, cell-based therapy for neuropathic itch that not only am

184 rogenesis that may ultimately lead to a stem cell-based therapy for osteoarthritis.

185 so is a potential candidate for developing a cell-based therapy for pre-existing autoimmune diseases.

186 king them an attractive candidate for use in cell-based therapy for seizures or other neuropsychiatri

187 olled trial) represents the largest study of cell-based therapy for STEMI completed in the United Sta

188 These findings suggest that cell-based therapy for stroke may be associated with cha

189 using this method which may further lead to cell-based therapy for treating corneal endothelial dysf

190 Growing interest in natural killer (NK) cell-based therapy for treating human cancer has made it

191 obstacles to be overcome in moving promising cell-based therapies from the laboratory to the clinic i

192 All types of cell-based therapies, from donor lymphocyte infusion to

193 application of protein and peptide therapy, cell-based therapy, genetic therapy, application of scaf

194 success of chimeric antigen receptor (CAR) T-cell based therapies greatly rely on the capacity to ide

195 d feasibility of the clinical application of cell-based therapy has been demonstrated, and promising

196 Cell-based therapy has been viewed as a promising altern

197 On the basis of several preclinical studies, cell-based therapy has emerged as a potential new therap

198 Stem cell-based therapy has emerged as a potential therapy in

199 Once this goal is achieved, then cell-based therapy has great promise for treatment of he

200 Stem cell-based therapy has recently been explored for the tr

201 y and prevent organ rejection; however, Treg cell-based therapies have been hampered by the technical

202 Cell-based therapies have shown encouraging results in b

203 Stem cell-based therapies have the potential to fundamentally

204 Stem cell-based therapies hold considerable promise for many

205 ion represents the first and most prescribed cell-based therapy; however, clinical safety and efficac

206 These data suggest that to optimize TR1 cell-based therapy, IL-10 receptor expression has to be

207 Although clinical studies have shown that cell-based therapies improve wound healing, the recruitm

208 Cs may represent a promising alternative for cell-based therapies in AD.

209 treat age-onset diseases and facilitate stem-cell-based therapies in older individuals.

210 dels indicate promise for the development of cell-based therapies in Parkinson's disease.

211 ovide significant advantages for autologous, cell-based therapies in regenerative medicine.

212 (i.e., personalized medicine), and enabling cell-based therapies in the clinic.

213 Determining the persistence of cell-based therapies in vivo is crucial to understanding

214 antially improve the efficacy of neural stem cell-based therapy in EAE/MS.

215 presents a significant step towards resident-cell-based therapy in human ischaemic heart disease.

216 controlled trials to evaluate the effect of cell-based therapy in patients with refractory angina wh

217 ability, and efficacy of mesenchymal stromal cell-based therapy in pilot clinical trials, including t

218 support future investigation of regulatory B cell-based therapy in the treatment of this disease.

219 Cell-based therapies, including immunoablation followed

220 on, important in free-radical formation; and cell-based therapies, including mesenchymal stem cells i

221 er of 2012, publicly traded companies in the cell-based therapy industry continued to show promising

222 tigation of these cells may help ensure that cell based-therapy is used safely and effectively in hum

223 Replacing lost retinal cells via stem cell-based therapies is an exciting, rapidly advancing a

224 potent stem cells for laboratory studies and cell-based therapies is hampered by their tumor-forming

225 Emerging research on cell-based therapies is opening a new door for patients

226 Although many obstacles remain, stem-cell-based therapy is a promising treatment to restore v

227 Cell-based therapy is envisaged as a useful therapeutic

228 A key aspect of cardiac cell-based therapy is the proper integration of newly fo

229 treatments, including cytokine treatment or cell-based therapy, is now available, although not all h

230 a major obstacle to the success of all stem cell-based therapies, many recent studies have sought to

231 terature suggests that current approaches of cell-based therapies may be helpful in ameliorating some

232 tering A2AR antagonists concurrently with NK cell-based therapies may heighten therapeutic benefits b

233 nt preclinical literature suggests that stem-cell-based therapies may offer promise, however the impa

234 ryonic or induced pluripotent stem cells for cell-based therapies of degenerative retinal diseases.

235 y T (iTreg) cells are a promising source for cell-based therapies of established inflammatory and aut

236 rials using mesenchymal stem cells (MSCs) in cell-based therapies of numerous diseases.

237 nction and may provide a source of cells for cell-based therapies of the inner ear.

238 ings have profound implications for the stem cell-based therapy of age-related diseases.

239 ferentiated cells may be highly suitable for cell-based therapy of chronic hepatocyte-depleting disor

240 ons for the derivation of beta-cells for the cell-based therapy of diabetes and sheds new light on th

241 and fibrosis, which limit the potential for cell-based therapy of the liver.

242 for progressive heart failure and death, and cell-based therapies offer new hope for these patients.

243 Cell-based therapies offer the potential to repair and r

244 Of the various cell-based therapy options, mesenchymal stem/stromal cel

245 edicine strengthens prospects for developing cell-based therapies or for promotion of endogenous repa

246 elial stem cells for the development of stem cell-based therapy or bioengineering SG tissues to repai

247 tive S1P3 antagonists for tolerizing DCs for cell-based therapy or for systemic administration for th

248 These developments, along with novel T cell-based therapies, position us to expand the assortme

249 Moreover, clinical trials of cell-based therapies present several unique methodologic

250 SDF-1alpha-engineered cell-based therapy promotes diabetic wound healing in mi

251 Increasing wound SDF-1alpha via cell-based therapy promotes healing in diabetic mice ( a

252 This cell-based therapy provides a novel therapeutic strategy

253 Cell-based therapies represent a promising strategy to t

254 Cell-based therapies represent promising strategies for

255 Cell-based therapy rescues retinal structure and functio

256 have important therapeutic implications for cell-based therapy strategies that use mixtures of CSCs

257 tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-viv

258 Cs) is crucial for the establishment of stem cell-based therapies targeting the treatment of immunolo

259 vide us with a strong basis for developing T cell-based therapy targeting this shared neoepitope.

260 It is unknown whether cell-based therapies that do not require transplantation

261 recent scientific advances in gene-based and cell-based therapies that might translate into novel the

262 atment strategies include the possibility of cell-based therapy that may reduce the severity of lung

263 A prototypic cell-based therapy, the mesenchymal stem cell, has succe

264 In cell-based therapies, therapeutic genes are expressed in

265 00 regenerative medicine products, including cell-based therapies, tissue-engineered biomaterials, sc

266 for the use of Notch-expanded progenitors in cell-based therapies to aid in the recovery of T-cells i

267 ws the present state of the art in gene- and cell-based therapies to correct cardiac rhythm disturban

268 Cell-based therapies to facilitate chimerism and achieve

269 lls have emerged as potential candidates for cell-based therapies to modulate the immune response in

270 valuate potential strategies for engineering cell-based therapies to overcome tumor associated immune

271 Stem cells hold great potential as cell-based therapies to promote vascularization and tiss

272 external pallidum could be a new target for cell-based therapies to reduce PD symptoms.

273 e potential provides significant promise for cell-based therapies to restore tissues or organs destro

274 away from studies on CE-derived spheres for cell-based therapies to restore vision in the degenerati

275 ic stem cells (ESCs) holds great promise for cell-based therapies to treat hematologic diseases.

276 We summarize here the status of cell-based therapies to treat multiple sclerosis and mak

277 establish a strategy for creating autologous cell-based therapies to treat patients with aggressive f

278 Cell-based therapies to treat retinal degeneration are n

279 RPOSE OF REVIEW: This review focuses on stem cell-based therapies to treat skeletal muscle disorders,

280 properties for developing new approaches in cell-based therapy to combat skeletal muscle wasting.

281 T cell adoptive transfer may be useful as a cell-based therapy to improve the efficacy and safety of

282 present the ideal autologous cell source for cell-based therapy to promote remyelination and neuropro

283 can be harnessed in the vascular context for cell-based therapy to remove artery wall mineral deposit

284 sults provide a foundation for an adult stem cell-based therapy to suppress soluble Abeta peptide and

285 em cells (MSCs) are promising candidates for cell-based therapy to treat several diseases and are com

286 For cell-based therapy to truly succeed, we must be able to

287 stem cell behavior are helping to move stem cell-based therapies toward the clinic.

288 tologous Chondrocyte Implantation (ACI) is a cell-based therapy used mainly for the treatment of chon

289 Cell-based therapy using mesenchymal stem cells (MSCs) s

290 Cell-based therapy using systemic infusion of GMSCs in e

291 odify the genomes of plants and animals, and cell-based therapies utilizing ZFNs are undergoing clini

292 Finally, in vivo efficacy of cell-based therapy was assessed in a xenotransplant femo

293 rations for eventual clinical application in cell-based therapies, we will need to control their diff

294 iving or were candidates to receive post-SCT cell-based therapies were not included in this analysis.

295 Moreover, the success of cell-based therapies will depend on a more comprehensive

296 ances in patient therapy are being made, and cell-based therapies with mesenchymal and hematopoietic

297 sequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimen

298 nt advances in gene, protein replacement, or cell-based therapies, with the purpose of delivering fun

299 fornia-based research groups to develop stem cell-based therapies within 4 years.

300 romal cells (BMSCs) hold great potential for cell-based therapy, yet the therapeutic efficacy remains